LifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases

Investment to allow Caldan to translate work on free fatty acid receptors initiated in their laboratories

Kymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies

The agreement will enable LifeArc to enhance our antibody drug discovery capabilities

LifeArc invests £1.5 million in Ducentis BioTherapeutics

LifeArc’s Seed Fund has invested £1.5 million in Ducentis BioTherapeutics to develop novel drug therapies for inflammatory and autoimmune disease

LifeArc monetises Keytruda® royalty interests to fund further research and investment

LifeArc receives US$1.3bn for a portion of royalty interests in Keytruda (pembrolizumab), making us one of the UK’s leading medical research charities by size of investment assets

Medicines Discovery Catapult and LifeArc launch strategic R&D partnership in biomarker discovery and proteomics technology

Three-year partnership to fund clinical application of biomarker strategies to help progress novel drug candidates to clinical evaluation stage

LifeArc and The University of Kent collaborate to develop potential pain medicines

Three-year programme will focus on ion channel drug discovery, to evaluate if small molecule modulators, optimised as part of the research, could show efficacy in treating chronic pain.

LifeArc licenses lead stage molecules to Daiichi Sankyo

London UK, April 16, 2019: LifeArc, one of the UK’s leading medical research charities, has signed a…

Cancer Research UK, Lifearc and Ono Pharma Form Cancer Immunotherapy Alliance

New immunotherapy drug targets for cancer will be progressed through a multimillion-pound drug discovery alliance announced today (Wednesday) between Cancer Research UK, LifeArc and Ono Pharmaceutical Co., Ltd.

Alliance enables clinical trial of experimental treatment for epidermolysis bullosa

An experimental medicine to treat the rare inherited skin disorder epidermolysis bullosa (EB) is on track to start trials in patients thanks to the perseverance of the charity team at LifeArc.